Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Geuna

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 1, 1995
Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune functionL Durelli, M R Bongioanni, R Cavallo, et al.
Neurology|July 1, 1996
Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatmentL Durelli, M R Bongioanni, B Ferrero, et al.
Neurology|March 1, 1994
Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosisL Durelli, M R Bongioanni, R Cavallo, et al.
Panminerva Medica|March 1, 1997
A case-control study on lymphocytic subsets in elderly bearing a gastroenteric cancerM Nano, M Molaschi, C Scarafiotti, et al.
Advances in Neuroimmunology|January 1, 1996
Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectorsE Oberholtzer, M Contarini, F Veglia, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 1, 1995
Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune functionL Durelli, M R Bongioanni, R Cavallo, et al.
Neurology|July 1, 1996
Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatmentL Durelli, M R Bongioanni, B Ferrero, et al.
Neurology|March 1, 1994
Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosisL Durelli, M R Bongioanni, R Cavallo, et al.
Panminerva Medica|March 1, 1997
A case-control study on lymphocytic subsets in elderly bearing a gastroenteric cancerM Nano, M Molaschi, C Scarafiotti, et al.
Advances in Neuroimmunology|January 1, 1996
Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectorsE Oberholtzer, M Contarini, F Veglia, et al.
Leukemia|March 16, 2007
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaA C Rawstron, N Villamor, M Ritgen, et al.
Pageof 5